Cellectar Biosciences (CLRB) Insider Trading & Ownership $4.82 +0.09 (+1.92%) Closing price 07/3/2025 03:52 PM EasternExtended Trading$5.00 +0.18 (+3.71%) As of 07/3/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Cellectar Biosciences (NASDAQ:CLRB) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage5.04%Number OfInsiders Buying(Last 12 Months)3Amount OfInsider Buying(Last 12 Months)$133.15KNumber OfInsiders Selling(Last 12 Months)0 Get CLRB Insider Trade Alerts Want to know when executives and insiders are buying or selling Cellectar Biosciences stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CLRB Insider Buying and Selling by Quarter Cellectar Biosciences Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/2/2025Chad J KoleanCFOBuy5,000$4.99$24,950.00 7/2/2025James V CarusoCEOBuy10,000$4.99$49,900.00 7/2/2025Jarrod LongcorCOOBuy10,000$4.99$49,900.00 1/10/2025Jarrod LongcorCOOBuy1,000$8.40$8,400.00 (Data available from 1/1/2013 forward) CLRB Insider Trading Activity - Frequently Asked Questions Who is on Cellectar Biosciences' Insider Roster? The list of insiders at Cellectar Biosciences includes Chad J Kolean, James V Caruso, and Jarrod Longcor. Learn more on insiders at CLRB. What percentage of Cellectar Biosciences stock is owned by insiders? 5.04% of Cellectar Biosciences stock is owned by insiders. Learn more on CLRB's insider holdings. Which Cellectar Biosciences insiders have been buying company stock? The following insiders have purchased CLRB shares in the last 24 months: Chad J Kolean ($24,950.00), James V Caruso ($49,900.00), and Jarrod Longcor ($58,300.00). How much insider buying is happening at Cellectar Biosciences? Insiders have purchased a total of 26,000 CLRB shares in the last 24 months for a total of $133,150.00 bought. More Insider Trading Tools from MarketBeat Related Companies MNOV Insider Trades ADAP Insider Trades ANRO Insider Trades CLSD Insider Trades BMEA Insider Trades RENB Insider Trades ANEB Insider Trades IMMX Insider Trades RPTX Insider Trades ASRT Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insider Selling at NVIDIA Could Turn Into an Opportunity The Top Insider Sells From Q2: Buy, Sell, or Hold?3 Hot Trades for Insiders, But Are They Good Buys for Investors?Insiders Chase Income and Stability in American Tower—Here’s Why3 Tech Stocks With High and Rising Institutional Interest This page (NASDAQ:CLRB) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
